NCT00316160

Sexual Functioning Study With Antidepressants

A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active Controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (WELLBUTRIN XL, 150-450 mg/Day) and Extended-release Venlafaxine (EFFEXOR XR, 75-225 mg/Day) in Subjects With Major Depressive Disorder

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 347 (planned)
• Sponsor: GlaxoSmithKline · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Effects of two depression medication on sexual functioning

Detailed description

A Twelve-week, Multi-center, Randomized, Double-blind, Double-dummy, Parallel-group, Active controlled, Escalating Dose Study to Compare the Effects on Sexual Functioning of Bupropion Hydrochloride Extended-release (WELLBUTRIN XL, 150-450 mg/day) and Extended-release Venlafaxine (EFFEXOR XR, 75-225 mg/day) in Subjects with Major Depressive Disorder

Conditions

• Depressive Disorder, Major
• Major Depressive Disorder (MDD)

Interventions

Type	Name	Description
DRUG	Bupropion Hydrochloride Extended-release
DRUG	Extended-release Venlafaxine

Timeline

• Start date: 2004-09-01
• Primary completion: 2005-05-01
• Completion: 2005-05-01
• First posted: 2006-04-20
• Last updated: 2017-05-30

Locations

45 sites across 1 country: United States